Metabolic alterations in cardiopulmonary vascular dysfunction

dc.contributor.author
Françoise Smolders, Valérie
dc.contributor.author
Zodda, Erika
dc.contributor.author
Quax, Paul H. A.
dc.contributor.author
Carini, Marina
dc.contributor.author
Barberà i Mir, Joan Albert
dc.contributor.author
Thomson, Timothy M.
dc.contributor.author
Tura-Ceide, Olga
dc.contributor.author
Cascante i Serratosa, Marta
dc.date.issued
2019-09-12T16:04:33Z
dc.date.issued
2019-09-12T16:04:33Z
dc.date.issued
2019-01-22
dc.date.issued
2019-09-12T16:04:33Z
dc.identifier
2296-889X
dc.identifier
https://hdl.handle.net/2445/139909
dc.identifier
687260
dc.identifier
30723719
dc.description.abstract
Cardiovascular diseases (CVD) are the leading cause of death worldwide. CVD comprise a range of diseases affecting the functionality of the heart and blood vessels, including acute myocardial infarction (AMI) and pulmonary hypertension (PH). Despite their different causative mechanisms, both AMI and PH involve narrowed or blocked blood vessels, hypoxia, and tissue infarction. The endothelium plays a pivotal role in the development of CVD. Disruption of the normal homeostasis of endothelia, alterations in the blood vessel structure, and abnormal functionality are essential factors in the onset and progression of both AMI and PH. An emerging theory proposes that pathological blood vessel responses and endothelial dysfunction develop as a result of an abnormal endothelial metabolism. It has been suggested that, in CVD, endothelial cell metabolism switches to higher glycolysis, rather than oxidative phosphorylation, as the main source of ATP, a process designated as the Warburg effect. The evidence of these alterations suggests that understanding endothelial metabolism and mitochondrial function may be central to unveiling fundamental mechanisms underlying cardiovascular pathogenesis and to identifying novel critical metabolic biomarkers and therapeutic targets. Here, we review the role of the endothelium in the regulation of vascular homeostasis and we detail key aspects of endothelial cell metabolism. We also describe recent findings concerning metabolic endothelial cell alterations in acute myocardial infarction and pulmonary hypertension, their relationship with disease pathogenesis and we discuss the future potential of pharmacological modulation of cellular metabolism in the treatment of cardiopulmonary vascular dysfunction. Although targeting endothelial cell metabolism is still in its infancy, it is a promising strategy to restore normal endothelial functions and thus forestall or revert the development of CVD in personalized multi-hit interventions at the metabolic level.
dc.format
14 p.
dc.format
application/pdf
dc.language
eng
dc.publisher
Frontiers Media
dc.relation
Reproducció del document publicat a: https://doi.org/10.3389/fmolb.2018.00120
dc.relation
Frontiers in Molecular Biosciences, 2019, vol. 5, p. 120
dc.relation
https://doi.org/10.3389/fmolb.2018.00120
dc.relation
info:eu-repo/grantAgreement/EC/H2020/675527/EU//MOGLYNET
dc.rights
cc-by (c) Françoise Smolders, Valérie et al., 2019
dc.rights
http://creativecommons.org/licenses/by/3.0/es
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Bioquímica i Biomedicina Molecular)
dc.subject
Malalties cardiovasculars
dc.subject
Cardiovascular diseases
dc.title
Metabolic alterations in cardiopulmonary vascular dysfunction
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Fitxers en aquest element

FitxersGrandàriaFormatVisualització

No hi ha fitxers associats a aquest element.